Related Experiment Video
Updated: Apr 24, 2026
14:04
Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
Published on: March 25, 2016
15.0K
Abstract:
On July 3, the FDA granted accelerated approval to Beleodaq, a histone deacetylase inhibitor, for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.
Insights
The FDA approved Beleodaq, a new histone deacetylase inhibitor, for treating relapsed or refractory peripheral T-cell lymphoma. This accelerated approval offers a new option for patients with this rare cancer.
Area of Science:
- Oncology
- Pharmacology
- Hematology
Background:
- Peripheral T-cell lymphoma (PTCL) is an aggressive non-Hodgkin lymphoma with limited treatment options.
- Relapsed or refractory PTCL presents a significant unmet medical need.
Related Concept Videos
02:56Treatment Resistant Cancers
2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
02:57Targeted Cancer Therapies
7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.0K